University of Birmingham – Confidence in Concept 2017
Lead Research Organisation:
University of Birmingham
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
Publications
Vögtle T
(2019)
Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B
in eLife
Sheriff L
(2020)
Alcoholic hepatitis and metabolic disturbance in female mice: a more tractable model than Nrf2-/- animals.
in Disease models & mechanisms
Chauhan A
(2020)
The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure.
in Nature communications
Wraith DC
(2021)
Peptide allergen-specific immunotherapy for allergic airway diseases-State of the art.
in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Siu J
(2021)
Cost-effectiveness of a weaning food safety and hygiene programme in rural Gambia.
in Tropical medicine & international health : TM & IH
Hill LJ
(2021)
ILB® resolves inflammatory scarring and promotes functional tissue repair.
in NPJ Regenerative medicine
| Description | Cancer Research UK Clinical Trial Fellowship in Paediatric Oncology |
| Amount | £69,979 (GBP) |
| Organisation | Birmingham Children's Hospital NHS Foundation Trust |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 01/2022 |
| Description | Dropping the Needle |
| Amount | £60,000 (GBP) |
| Organisation | Royal Academy of Engineering |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 12/2020 |
| Description | Dropping the needle: Injection-free drug delivery to the eye |
| Amount | £229,009 (GBP) |
| Funding ID | RPGF1910\218 |
| Organisation | The Dunhill Medical Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 11/2023 |
| Description | MRC precision medicine |
| Amount | £5,000,000 (GBP) |
| Funding ID | PO 3978284 |
| Organisation | MRC-Technology |
| Sector | Private |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 05/2024 |
| Description | Potential therapeutic targeting of CaMK1D in paediatric B cell lymphoma |
| Amount | £234,261 (GBP) |
| Organisation | Little Princess Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2022 |
| End | 07/2025 |
| Description | University of Birmingham Dynamic Investment Fund |
| Amount | £31,552 (GBP) |
| Organisation | University of Birmingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 06/2021 |
| Description | WT ISSF CDA In silicon drug design |
| Amount | £25,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 08/2022 |
| Description | Wellcome TDF: Development of Surface Plasmon Resonance (SPR) and Saturation Transfer Difference NMR spectroscopy (STD-NMR) to assess EAAT1 target engagement |
| Amount | £28,316 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2022 |
| End | 08/2022 |
| Title | ANTIGEN BINDING MOLECULES AND EPITOPES, AND USES THEREOF |
| Description | The invention provides an isolated antigenbinding molecule or fragment thereof which specifically binds to human G6b-B. The invention also provides for use of the antigen binding molecule or fragment thereof in treating a disease or disorder associated with dysregulated platelet homeostasis. |
| IP Reference | US2022112285 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | Not Availible |
| Title | CHEMOTHERAPEUTIC DRUG IMPLANT |
| Description | This invention relates to chemotherapeutic drug implants, and more particularly, to biodegradable chemotherapeutic drug implants comprising irinotecan, or derivatives or pharmaceutically acceptable salts thereof. The present invention also relates to processes for the preparation of these chemotherapeutic drug implants and to their use in therapy, in particular in treating brain tumours. |
| IP Reference | WO2021116701 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2021 |
| Licensed | Yes |
| Impact | Not available. Patent filed by Extruded Pharmaceuticals Ltd (EPL) for a Chemotherapeutic Drug Implant. |
| Title | DRUG DELIVERY SYSTEM |
| Description | The present invention relates to a drug delivery system and methods of using the delivery system, particularly a delivery system for transporting pharmaceutically active agents across, for example, the skin, the surface of the eye or mucosal membranes. The drug delivery system comprises a pharmaceutically effective moiety and a polyamine or amine moiety, wherein the polyamine or amine moiety does not comprise two or more contiguous basic amino acid residues. The drug delivery system may be provided for use as a medicament, or for use in the treatment of a disease or condition selected from eye disease, burns, infection, and trauma. The invention also provides a method comprising administering a pharmaceutically effective amount of the drug delivery system of the invention to a patient in need thereof. |
| IP Reference | WO2020148556 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | Not known at present. |
| Title | POLYSACCHARIDE COMPOSITIONS AND THERAPEUTIC GELS |
| Description | Provided are pharmaceutical compositions comprising a sulphated polysaccharide and a shear-thinning fluid gel. The sulphated polysaccharide may, by way of example, be selected from the group consisting of: a dextran sulphate having an average molecular weight of 10,000 Da or less; heparan sulphate; fucoidan; poligeenan; furcellaran; and a carrageenan. The shear-thinning fluid gel may comprise a microgel particle forming polymer, suitably selected from one or more of the following groups: gellans; alginates; carrageenans; agarose; chitosan; pectin; agarose; agar or gelatin. The compositions disclosed may be used for the prevention and/or treatment of glaucoma. These compositions may be used for the inhibition or reduction of fibrosis. The invention also relates to the medical uses of sulphated polysaccharides, and the medical uses of shear-thinning fluid gels. |
| IP Reference | WO2021250423 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2021 |
| Licensed | Yes |
| Impact | Information not available. Licensed to Healome Therapeutics Ltd |
| Title | TREATMENT OF EYE CONDITIONS |
| Description | The present disclosure relates to the treatment of eye conditions, by inhibiting Chk2 kinase. Particular ocular conditions may be associated with neuronal damage/dysfunction in the eye, or neurons in communication with the eye, which may result from, physical trauma, chemical means, infection, inflammation, hypoxia and/or interruption in blood supply, or be due to a neurodegenerative disorder and/or autoimmune disease. The Chk2 inhibitor may be a small molecule, protein, peptide or nucleic acid. Exemplary small molecule Chk2 inhibitors include PV1019, AZD7762, CCT241533, BML-277 or prexasertib. |
| IP Reference | WO2022084202 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | Not known at present. |
| Title | USES OF CHK2 INHIBITORS |
| Description | The present disclosure relates to the treatment of neurological conditions, by inhibiting Chk2 kinase. Particular neurological conditions may be associated with neuronal damage/dysfunction or neurological degeneration, which may result from, physical trauma, chemical means, infection, inflammation, hypoxia and/or interruption in blood supply, or be due to a neurodegenerative disorder and/or autoimmune disease. The Chk2 inhibitor may be a small molecule, protein, peptide or nucleic acid. Exemplary small molecule Chk2 inhibitors include PV1019, AZD7762, CCT241533, BML-277 or prexasertib. |
| IP Reference | WO2022084201 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | Not known at present. |
| Title | Chemoseed |
| Description | The results of this project have been used to secure the irinotecan-loaded drug eluting seed (ChemoSeed) a position within the BRAIN MATRIX clinical trial as a Phase I/II study. The data has been presented to the MHRA who fully support the development strategy. Extruded Pharmaceuticals Ltd, who own the IP around ChemoSeed, are currently in the process of securing the funding to take the irinotecan-loaded ChemoSeed through technology transfer, scale-up, GLP batch manufacture, GLP toxicity and pharmacokinetics and cGMP manufacture of a clinical batch. |
| Type | Therapeutic Intervention - Medical Devices |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2022 |
| Development Status | Actively seeking support |
| Impact | £150,000 Extruded Pharmaceuticals Ltd, investment |